Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to evaluate, at different times, the RV3278A - ET0943 cosmetic product efficacy after 8 weeks of application on the face (twice-daily application). At T1 (Baseline), T2 (4 weeks) and T3 (8 weeks), the following assessments are performed: - The reduction of the pilosebaceous follicular ostium size in vivo (pores) on the forehead - The clinical evaluation (count of non inflammatory and inflammatory acne lesions, IGA score) of the face - The reduction in visible follicles - The standardized numerical photographs of face and ¾ right and left profile in normal, parallel polarized, cross polarized and UV light - The analysis of the skin lipids of the forehead - The qualitative and quantitative analysis of the sebum and comedones constituents (nose wings) This is a comparative, open-labelled study, on subjects with oily and acne prone skins on the face. Each group includes 18 subjects.


Clinical Trial Description

This study is monocentric, comparative versus non-treated group, open-labelled, exploratory, conducted in adults having oily and acne prone skin. The study includes 4 visits for each group, including subjects' selection: - V0: Subjects' selection - V1: Baseline inclusion - V2: 4 weeks, follow-up visit - V3: 8 weeks, study end The maximal study duration is 61 days. The front, temporal areas and nose wings are defined as the study interest areas for superficial samples. The evaluation is at 3 times: T1 baseline, T2 at 4 weeks and T3 at 8 weeks of application of RV3278A formula ET0943 with comparison of each time versus baseline. There are twice-daily applications (morning and evening) of the test product on the face. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04873089
Study type Observational
Source Pierre Fabre Dermo Cosmetique
Contact
Status Completed
Phase
Start date September 17, 2018
Completion date December 21, 2018

See also
  Status Clinical Trial Phase
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Completed NCT04806594 - Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar. N/A
Recruiting NCT03465150 - Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital
Completed NCT02250859 - A Pharmacokinetic Study of Minocycline in Male and Female Volunteers Phase 1
Completed NCT01206348 - Combination Treatment for Moderate to Severe Acne Phase 4
Terminated NCT01193764 - Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris N/A
Completed NCT00725439 - An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne Phase 2
Completed NCT05640388 - Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
Recruiting NCT05941065 - Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin N/A
Recruiting NCT06120452 - A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation N/A
Completed NCT04300010 - Blue Light Therapy of C. Acnes Phase 4
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Completed NCT04559022 - Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring N/A
Terminated NCT02431494 - Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris N/A
Completed NCT05469880 - Efficacy and Tolerance of Formula 609613 37 in Acneic Patients N/A
Completed NCT02944461 - Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Phase 4
Completed NCT01951417 - Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Phase 4
Completed NCT01701024 - Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne Phase 3
Completed NCT01245946 - Photodynamic Therapy Compared to Adapalene 0.1% Gel Plus Doxycycline in the Treatment of Acne Vulgaris Phase 2